New drug hope for rare bone cancer patients

(Wellcome Trust Sanger Institute) Patients with a rare bone cancer of the skull and spine -- chordoma -- could be helped by existing drugs, suggest scientists from the Wellcome Trust Sanger Institute, University College London Cancer Institute and the Royal National Orthopaedic Hospital NHS Trust. In the largest genomics study of chordoma to date, published today in Nature Communications, scientists show that a group of chordoma patients have mutations in genes that are the target of existing drugs, known as PI3K inhibitors.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news